Search

everythinglearnresearchcommunity

for

Search:↓

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Systemic corticosteroids don't prevent severe alopecia areata from spreading or relapsing.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

High-dose corticosteroids and methotrexate had a modest effect on severe childhood alopecia, but side effects and relapse were concerns.

Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.

The article suggests a treatment plan for a stubborn scalp condition common in elderly Australians to help improve their lives.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.

Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.

Alopecia areata in children is usually mild and effectively treated with strong topical steroids.

Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.

Frontal fibrosing alopecia has a higher remission rate than lichen planopilaris.

Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.

About half of people with mild alopecia areata see hair regrowth in a year, but relapses are common.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

Endoscopic forehead and brow lifting safely and consistently improves aged eyebrows, but may have complications.

A 13-year-old girl with various symptoms was successfully treated for autoimmune disease using the antibiotic co-trimoxazole.

A 13-year-old girl with various symptoms was successfully treated with an antibiotic called co-trimoxazole.